Dimensional Fund Advisors LP Acquires 10,491 Shares of INmune Bio, Inc. (NASDAQ:INMB)

Dimensional Fund Advisors LP grew its position in INmune Bio, Inc. (NASDAQ:INMB) by 71.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 25,139 shares of the company’s stock after purchasing an additional 10,491 shares during the quarter. Dimensional Fund Advisors LP owned about 0.11% of INmune Bio worth $117,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Raymond James Financial Inc. acquired a new position in INmune Bio during the fourth quarter valued at $2,221,000. Renaissance Technologies LLC raised its position in shares of INmune Bio by 73.3% during the 4th quarter. Renaissance Technologies LLC now owns 185,800 shares of the company’s stock worth $868,000 after purchasing an additional 78,600 shares during the last quarter. Walleye Capital LLC purchased a new stake in INmune Bio during the 4th quarter valued at about $157,000. Barclays PLC grew its stake in INmune Bio by 601.9% during the 3rd quarter. Barclays PLC now owns 29,044 shares of the company’s stock valued at $157,000 after acquiring an additional 24,906 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in INmune Bio by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 363,602 shares of the company’s stock valued at $1,698,000 after acquiring an additional 19,136 shares in the last quarter. 12.72% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on INMB shares. Rodman & Renshaw started coverage on shares of INmune Bio in a research report on Tuesday, January 28th. They set a “buy” rating and a $23.00 price objective for the company. Maxim Group raised their price objective on shares of INmune Bio from $22.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, February 13th. Scotiabank increased their target price on shares of INmune Bio from $22.00 to $23.00 and gave the company a “sector outperform” rating in a research report on Tuesday, February 11th. Finally, RODMAN&RENSHAW upgraded shares of INmune Bio to a “strong-buy” rating in a research note on Tuesday, January 28th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, INmune Bio currently has a consensus rating of “Buy” and a consensus target price of $22.80.

INmune Bio Stock Up 7.8%

INmune Bio stock opened at $7.86 on Friday. The firm has a fifty day moving average of $7.64 and a 200-day moving average of $6.93. The firm has a market capitalization of $180.65 million, a P/E ratio of -3.61 and a beta of 1.63. INmune Bio, Inc. has a 52-week low of $4.32 and a 52-week high of $11.30.

INmune Bio (NASDAQ:INMB) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.43) earnings per share for the quarter, hitting the consensus estimate of ($0.43). The company had revenue of $0.05 million for the quarter. On average, research analysts expect that INmune Bio, Inc. will post -2.24 EPS for the current fiscal year.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.